172 related articles for article (PubMed ID: 25524139)
1. Changes in serotonin transporter (5-HTT) gene expression in peripheral blood cells after MDMA intake.
Yubero-Lahoz S; Kuypers KP; Ramaekers JG; Langohr K; Farré M; de la Torre R
Psychopharmacology (Berl); 2015 Jun; 232(11):1921-9. PubMed ID: 25524139
[TBL] [Abstract][Full Text] [Related]
2. Memory function and serotonin transporter promoter gene polymorphism in ecstasy (MDMA) users.
Reneman L; Schilt T; de Win MM; Booij J; Schmand B; van den Brink W; Bakker O
J Psychopharmacol; 2006 May; 20(3):389-99. PubMed ID: 16574713
[TBL] [Abstract][Full Text] [Related]
3. Long-term neuronal damage and recovery after a single dose of MDMA: expression and distribution of serotonin transporter in the rat brain.
Kirilly E
Neuropsychopharmacol Hung; 2010 Sep; 12(3):413-23. PubMed ID: 20962361
[TBL] [Abstract][Full Text] [Related]
4. Clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy"): the influence of gender and genetics (CYP2D6, COMT, 5-HTT).
Pardo-Lozano R; Farré M; Yubero-Lahoz S; O'Mathúna B; Torrens M; Mustata C; Pérez-Mañá C; Langohr K; Cuyàs E; Carbó Ml; de la Torre R
PLoS One; 2012; 7(10):e47599. PubMed ID: 23112822
[TBL] [Abstract][Full Text] [Related]
5. Role of Serotonin Transporter and Receptor Gene Variations in the Acute Effects of MDMA in Healthy Subjects.
Vizeli P; Meyer Zu Schwabedissen HE; Liechti ME
ACS Chem Neurosci; 2019 Jul; 10(7):3120-3131. PubMed ID: 30589533
[TBL] [Abstract][Full Text] [Related]
6. 3,4-methylenedioxymethamphetamine induces gene expression changes in rats related to serotonergic and dopaminergic systems, but not to neurotoxicity.
Cuyas E; Robledo P; Pizarro N; Farré M; Puerta E; Aguirre N; de la Torre R
Neurotox Res; 2014 Feb; 25(2):161-9. PubMed ID: 23949956
[TBL] [Abstract][Full Text] [Related]
7. Depressive mood ratings are reduced by MDMA in female polydrug ecstasy users homozygous for the l-allele of the serotonin transporter.
Kuypers KPC; de la Torre R; Farre M; Xicota L; de Sousa Fernandes Perna EB; Theunissen EL; Ramaekers JG
Sci Rep; 2018 Jan; 8(1):1061. PubMed ID: 29348651
[TBL] [Abstract][Full Text] [Related]
8. Mood, cognition and serotonin transporter availability in current and former ecstasy (MDMA) users: the longitudinal perspective.
Thomasius R; Zapletalova P; Petersen K; Buchert R; Andresen B; Wartberg L; Nebeling B; Schmoldt A
J Psychopharmacol; 2006 Mar; 20(2):211-25. PubMed ID: 16510479
[TBL] [Abstract][Full Text] [Related]
9. A voxel-based PET investigation of the long-term effects of "Ecstasy" consumption on brain serotonin transporters.
Buchert R; Thomasius R; Wilke F; Petersen K; Nebeling B; Obrocki J; Schulze O; Schmidt U; Clausen M
Am J Psychiatry; 2004 Jul; 161(7):1181-9. PubMed ID: 15229049
[TBL] [Abstract][Full Text] [Related]
10. Single dose of MDMA causes extensive decrement of serotoninergic fibre density without blockage of the fast axonal transport in Dark Agouti rat brain and spinal cord.
Kovács GG; Andó RD; Adori C; Kirilly E; Benedek A; Palkovits M; Bagdy G
Neuropathol Appl Neurobiol; 2007 Apr; 33(2):193-203. PubMed ID: 17359360
[TBL] [Abstract][Full Text] [Related]
11. Effects of 3,4-methylenedioxymethamphetamine (MDMA) on serotonin transporter and vesicular monoamine transporter 2 protein and gene expression in rats: implications for MDMA neurotoxicity.
Biezonski DK; Meyer JS
J Neurochem; 2010 Feb; 112(4):951-62. PubMed ID: 20002520
[TBL] [Abstract][Full Text] [Related]
12. The effect of polymorphism at the serotonin transporter gene on decision-making, memory and executive function in ecstasy users and controls.
Roiser JP; Rogers RD; Cook LJ; Sahakian BJ
Psychopharmacology (Berl); 2006 Oct; 188(2):213-27. PubMed ID: 16941121
[TBL] [Abstract][Full Text] [Related]
13. Serotonin transporter genotype and acute subjective response to amphetamine.
Lott DC; Kim SJ; Cook EH; de Wit H
Am J Addict; 2006; 15(5):327-35. PubMed ID: 16966188
[TBL] [Abstract][Full Text] [Related]
14. 5-HTTLPR polymorphism, mood disorders and MDMA use in a 3-year follow-up study.
Martín-Santos R; Torrens M; Poudevida S; Langohr K; Cuyás E; Pacifici R; Farré M; Pichini S; de la Torre R
Addict Biol; 2010 Jan; 15(1):15-22. PubMed ID: 19878141
[TBL] [Abstract][Full Text] [Related]
15. Mood, cognition and serotonin transporter availability in current and former ecstasy (MDMA) users.
Thomasius R; Petersen K; Buchert R; Andresen B; Zapletalova P; Wartberg L; Nebeling B; Schmoldt A
Psychopharmacology (Berl); 2003 Apr; 167(1):85-96. PubMed ID: 12632248
[TBL] [Abstract][Full Text] [Related]
16. Neuroimaging research in human MDMA users: a review.
Cowan RL
Psychopharmacology (Berl); 2007 Jan; 189(4):539-56. PubMed ID: 16847678
[TBL] [Abstract][Full Text] [Related]
17. Gender differences in the subjective effects of MDMA.
Liechti ME; Gamma A; Vollenweider FX
Psychopharmacology (Berl); 2001 Mar; 154(2):161-8. PubMed ID: 11314678
[TBL] [Abstract][Full Text] [Related]
18. In vivo imaging of cerebral serotonin transporter and serotonin(2A) receptor binding in 3,4-methylenedioxymethamphetamine (MDMA or "ecstasy") and hallucinogen users.
Erritzoe D; Frokjaer VG; Holst KK; Christoffersen M; Johansen SS; Svarer C; Madsen J; Rasmussen PM; Ramsøy T; Jernigan TL; Knudsen GM
Arch Gen Psychiatry; 2011 Jun; 68(6):562-76. PubMed ID: 21646575
[TBL] [Abstract][Full Text] [Related]
19. Sub-acute effects of MDMA (+/-3,4-methylenedioxymethamphetamine, "ecstasy") on mood: evidence of gender differences.
Verheyden SL; Hadfield J; Calin T; Curran HV
Psychopharmacology (Berl); 2002 Apr; 161(1):23-31. PubMed ID: 11967627
[TBL] [Abstract][Full Text] [Related]
20. Human pharmacology of 3,4-methylenedioxymethamphetamine ("ecstasy"): psychomotor performance and subjective effects.
Cami J; Farré M; Mas M; Roset PN; Poudevida S; Mas A; San L; de la Torre R
J Clin Psychopharmacol; 2000 Aug; 20(4):455-66. PubMed ID: 10917407
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
